Volume Alert - MRK 59.26 Merck & Company $MRK Hit a high today of 59.90 Closing the day 11/06/14 at 59.26 -0.31 -0.52% With a day low of 59.19 and a total volume of 13,362,121.
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Dow Jones (DJIA) Today: Merck (MRK) Lower
at The Street - Thu Nov 06, 12:00PM CST
Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a 33-cent decline (-0.6%) bringing the stock to $59.24.
MRK: 59.26 (-0.31)
New Studies Investigating the Use of KEYTRUDA(R) (pembrolizumab), Merck's Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
Business Wire - Thu Nov 06, 8:08AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA(R) (pembrolizumab) - the company's anti-PD-1 therapy - in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 - 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 - 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 - 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types.
MRK: 59.26 (-0.31)
Stock Futures Shed Losses, Rise; Sierra Wireless, Tableau Rocket
at Investor's Business Daily - Thu Nov 06, 7:58AM CST
Stock futures reversed early losses to point firmly higher ahead of Thursday's open. Dow futures sloughed off a 26-point decline and were up 26.5 points. Nasdaq 100 futures backed out of a 10-point loss to trade 4.2 points above fair market value....
TSLA: 241.22 (+10.25), SWIR: 33.60 (+7.06), V: 250.09 (+0.56), AXP: 91.58 (-0.84), MRK: 59.26 (-0.31), DATA: 84.29 (+7.79), CSCO: 25.26 (+0.11)
BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 6:30AM CST
--- Strengthened management and Board including Chief Medical Officer -
MRK: 59.26 (-0.31), BIND: 8.74 (+0.19)
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin(TM) Nanomedicines for Oncology
Business Wire - Thu Nov 06, 6:25AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio.
MRK: 59.26 (-0.31), BIND: 8.74 (+0.19)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 250.38 (+2.47), LMT: 189.88 (+0.15), XOM: 96.26 (+1.19), ILMN: 189.87 (+3.50), AKS: 6.14 (-0.09), KORS: 72.31 (-0.09), PAYX: 47.57 (-0.20), RIG: 29.92 (+1.03), EOG: 98.97 (+2.87), COST: 137.09 (+0.59), TWTR: 40.84 (+0.47), OXY: 86.40 (-0.07), KO: 42.29 (-0.02), SEAS: 18.84 (+0.14), TMO: 118.91 (+0.36), NUE: 53.48 (+0.42), TRIP: 74.00 (+2.05), DISCA: 32.90 (-1.57), CHUY: 22.00 (+1.32), LB: 76.35 (+1.35), GEO: 40.64 (+0.74), ESV: 40.50 (+0.49), MPC: 93.13 (+2.42), BAX: 71.60 (+0.70), MRK: 59.26 (-0.31), EXPE: 84.06 (+1.01), STI: 39.82 (+0.22)
SANS Institute Announces Healthcare Cyber Security Summit Speaker Line-Up
PR Newswire - Wed Nov 05, 10:02AM CST
The SANS Institute today announced the speaker line-up for its second annual Healthcare Cyber Security Summit in San Francisco on December 3rd. Included among the speaker list are security experts from Aetna, Kaiser Permanente, Merck and Phoenix Children's Hospital.
MRK: 59.26 (-0.31)
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 59.26 (-0.31), SHPG: 199.95 (+1.34)
Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
Business Wire - Wed Nov 05, 7:30AM CST
--Final stage to focus on planned in-field use studies
MRK: 59.26 (-0.31)
Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer
GlobeNewswire - Wed Nov 05, 6:46AM CST
Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to conduct the first-in-human study of ADXS31-142 for the treatment of metastatic castration resistant prostate cancer (mCRPC). ADXS31-142 is Advaxis's lead Lm-LLO immunotherapy designed to specifically target prostate-specific antigen (PSA).
ADXS: 2.83 (-0.19), MRK: 59.26 (-0.31)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 250.38 (+2.47), ECYT: 6.49 (+0.99), MRK: 59.26 (-0.31), HSP: 56.64 (+3.54)
Watch for Shares of Merck (MRK) to Approach Resistance at $59.83
Comtex SmarTrend(R) - Tue Nov 04, 8:58AM CST
Shares of Merck (NYSE:MRK) opened today above their pivot of $58.47 and have already reached the first level of resistance at $59.38. Analysts will be watching for a cross of the next upside pivot targets of $59.83 and $61.19.
MRK: 59.26 (-0.31)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.35 (-0.05), SHPG: 199.95 (+1.34), MRK: 59.26 (-0.31), PFE: 30.04 (unch), SNY: 45.86 (+0.16)
1 in 4 Physicians Went Online After Meeting with a Pharmaceutical Sales Rep
PRWeb - Tue Nov 04, 7:09AM CST
Digital Insights Group today announced the latest update to DIG™ Connected Physician is available to clients. The DIG™ Connected Physician series provides clients with strategic insights into digital and technology trends among US physicians with new insights every quarter. In addition to market insights, DIG offers clients the ability to drill down into their customer and specialty segments of interest in much greater detail - such as physicians engaging with their reps or visiting their properties online.
MRK: 59.26 (-0.31), NVS: 92.03 (-0.60)
Karyopharm Appoints J. Scott Garland to Its Board of Directors
GlobeNewswire - Tue Nov 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa Inc., to the company's board of directors.
RLYP: 20.31 (-0.27), MRK: 59.26 (-0.31), AMGN: 160.35 (+1.41), KPTI: 41.73 (+4.02)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 59.26 (-0.31), CDXS: 2.42 (+0.04)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
PR Newswire - Mon Nov 03, 12:47PM CST
Research and Markets has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering.
MRK: 59.26 (-0.31)
Global Pearl/Effect Pigments Industry Outlook 2019
M2 - Mon Nov 03, 9:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/zzsscw/global) has announced the addition of the "Global Pearl/Effect Pigments Industry Report 2014" report to their offering. The report provides an overview of the industry including definitions, classifications, applications and industry chain structure. The pearl/effects pigments market analysis is provided for both the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Pearl/effects pigments industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on seventeen industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The pearl/effects pigments industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Pearl/Effect Pigments Industry Overview - Pearl/Effect Pigments International and China Market Analysis - Pearl/Effect Pigments Technical Data and Manufacturing Plants Analysis - Pearl/Effect Pigments Production by Regions By Technology By Applications - Pearl/Effect Pigments Manufacturing Process and Cost Structure - 2009-2014 Pearl/Effect Pigments Productions Supply Sales Demand Market Status and Forecast - Pearl/Effect Pigments Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Pearl/Effect Pigments Marketing Channels Analysis - Pearl/Effect Pigments Industry Development Trend - Pearl/Effect Pigments Industry Development Proposals - Pearl/Effect Pigments New Project Investment Feasibility Analysis - Global and China Pearl/Effect Pigments Industry Research Conclusions Companies Mentioned - Altana - Aoke - BASF - CQV - Chenguang - Impact Colors - Kelly - Kuncai - Longhua - Merck - Oxen - Rika - Ruicheng - Sudarshan - Sun Chemical - Tiancai - Volor For more information visit http://www.researchandmarkets.com/research/zzsscw/global
MRK: 59.26 (-0.31)
Stock Market News for November 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 9:10AM CST
Bank of Japan’s unanticipated expansion in monetary stimulus helped benchmarks to finish at record highs on Friday
VRX: 128.77 (-3.14), HAL: 53.17 (+0.80), XOM: 96.26 (+1.19), SLB: 96.98 (+0.34), YHOO: 47.93 (+0.47), GS: 191.00 (+1.16), V: 250.09 (+0.56), CMI: 146.64 (+2.52), CHK: 22.76 (unch), MRK: 59.26 (-0.31), EOG: 98.97 (+2.87), ABBV: 62.71 (+0.17), CAT: 100.91 (+1.50), CVX: 118.53 (+1.48), AAPL: 108.70 (-0.16), MA: 85.75 (-0.24)
The Zacks Analyst Blog Highlights: Goldman Sachs Group, Visa, DuPont, Merck and Pfizer
PR Newswire - Mon Nov 03, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Goldman Sachs Group, Inc. (NYSE:GS-Free Report), Visa Inc. (NYSE:V-Free Report), DuPont (NYSE
D-Free Report), Merck & Co. (NYSE:MRK-Free Report) and Pfizer Inc. (NYSE
FE-Free Report).
V: 250.09 (+0.56), MRK: 59.26 (-0.31)
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Dow Jones (DJIA) Today: Merck (MRK) Lower
at The Street - Thu Nov 06, 12:00PM CST
Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a 33-cent decline (-0.6%) bringing the stock to $59.24.
MRK: 59.26 (-0.31)
New Studies Investigating the Use of KEYTRUDA(R) (pembrolizumab), Merck's Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
Business Wire - Thu Nov 06, 8:08AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA(R) (pembrolizumab) - the company's anti-PD-1 therapy - in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 - 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 - 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 - 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types.
MRK: 59.26 (-0.31)
Stock Futures Shed Losses, Rise; Sierra Wireless, Tableau Rocket
at Investor's Business Daily - Thu Nov 06, 7:58AM CST
Stock futures reversed early losses to point firmly higher ahead of Thursday's open. Dow futures sloughed off a 26-point decline and were up 26.5 points. Nasdaq 100 futures backed out of a 10-point loss to trade 4.2 points above fair market value....
TSLA: 241.22 (+10.25), SWIR: 33.60 (+7.06), V: 250.09 (+0.56), AXP: 91.58 (-0.84), MRK: 59.26 (-0.31), DATA: 84.29 (+7.79), CSCO: 25.26 (+0.11)
BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 6:30AM CST
--- Strengthened management and Board including Chief Medical Officer -
MRK: 59.26 (-0.31), BIND: 8.74 (+0.19)
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin(TM) Nanomedicines for Oncology
Business Wire - Thu Nov 06, 6:25AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio.
MRK: 59.26 (-0.31), BIND: 8.74 (+0.19)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 250.38 (+2.47), LMT: 189.88 (+0.15), XOM: 96.26 (+1.19), ILMN: 189.87 (+3.50), AKS: 6.14 (-0.09), KORS: 72.31 (-0.09), PAYX: 47.57 (-0.20), RIG: 29.92 (+1.03), EOG: 98.97 (+2.87), COST: 137.09 (+0.59), TWTR: 40.84 (+0.47), OXY: 86.40 (-0.07), KO: 42.29 (-0.02), SEAS: 18.84 (+0.14), TMO: 118.91 (+0.36), NUE: 53.48 (+0.42), TRIP: 74.00 (+2.05), DISCA: 32.90 (-1.57), CHUY: 22.00 (+1.32), LB: 76.35 (+1.35), GEO: 40.64 (+0.74), ESV: 40.50 (+0.49), MPC: 93.13 (+2.42), BAX: 71.60 (+0.70), MRK: 59.26 (-0.31), EXPE: 84.06 (+1.01), STI: 39.82 (+0.22)
SANS Institute Announces Healthcare Cyber Security Summit Speaker Line-Up
PR Newswire - Wed Nov 05, 10:02AM CST
The SANS Institute today announced the speaker line-up for its second annual Healthcare Cyber Security Summit in San Francisco on December 3rd. Included among the speaker list are security experts from Aetna, Kaiser Permanente, Merck and Phoenix Children's Hospital.
MRK: 59.26 (-0.31)
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 59.26 (-0.31), SHPG: 199.95 (+1.34)
Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
Business Wire - Wed Nov 05, 7:30AM CST
--Final stage to focus on planned in-field use studies
MRK: 59.26 (-0.31)
Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer
GlobeNewswire - Wed Nov 05, 6:46AM CST
Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to conduct the first-in-human study of ADXS31-142 for the treatment of metastatic castration resistant prostate cancer (mCRPC). ADXS31-142 is Advaxis's lead Lm-LLO immunotherapy designed to specifically target prostate-specific antigen (PSA).
ADXS: 2.83 (-0.19), MRK: 59.26 (-0.31)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 250.38 (+2.47), ECYT: 6.49 (+0.99), MRK: 59.26 (-0.31), HSP: 56.64 (+3.54)
Watch for Shares of Merck (MRK) to Approach Resistance at $59.83
Comtex SmarTrend(R) - Tue Nov 04, 8:58AM CST
Shares of Merck (NYSE:MRK) opened today above their pivot of $58.47 and have already reached the first level of resistance at $59.38. Analysts will be watching for a cross of the next upside pivot targets of $59.83 and $61.19.
MRK: 59.26 (-0.31)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.35 (-0.05), SHPG: 199.95 (+1.34), MRK: 59.26 (-0.31), PFE: 30.04 (unch), SNY: 45.86 (+0.16)
1 in 4 Physicians Went Online After Meeting with a Pharmaceutical Sales Rep
PRWeb - Tue Nov 04, 7:09AM CST
Digital Insights Group today announced the latest update to DIG™ Connected Physician is available to clients. The DIG™ Connected Physician series provides clients with strategic insights into digital and technology trends among US physicians with new insights every quarter. In addition to market insights, DIG offers clients the ability to drill down into their customer and specialty segments of interest in much greater detail - such as physicians engaging with their reps or visiting their properties online.
MRK: 59.26 (-0.31), NVS: 92.03 (-0.60)
Karyopharm Appoints J. Scott Garland to Its Board of Directors
GlobeNewswire - Tue Nov 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa Inc., to the company's board of directors.
RLYP: 20.31 (-0.27), MRK: 59.26 (-0.31), AMGN: 160.35 (+1.41), KPTI: 41.73 (+4.02)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 59.26 (-0.31), CDXS: 2.42 (+0.04)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
PR Newswire - Mon Nov 03, 12:47PM CST
Research and Markets has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering.
MRK: 59.26 (-0.31)
Global Pearl/Effect Pigments Industry Outlook 2019
M2 - Mon Nov 03, 9:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/zzsscw/global) has announced the addition of the "Global Pearl/Effect Pigments Industry Report 2014" report to their offering. The report provides an overview of the industry including definitions, classifications, applications and industry chain structure. The pearl/effects pigments market analysis is provided for both the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Pearl/effects pigments industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on seventeen industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The pearl/effects pigments industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Pearl/Effect Pigments Industry Overview - Pearl/Effect Pigments International and China Market Analysis - Pearl/Effect Pigments Technical Data and Manufacturing Plants Analysis - Pearl/Effect Pigments Production by Regions By Technology By Applications - Pearl/Effect Pigments Manufacturing Process and Cost Structure - 2009-2014 Pearl/Effect Pigments Productions Supply Sales Demand Market Status and Forecast - Pearl/Effect Pigments Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Pearl/Effect Pigments Marketing Channels Analysis - Pearl/Effect Pigments Industry Development Trend - Pearl/Effect Pigments Industry Development Proposals - Pearl/Effect Pigments New Project Investment Feasibility Analysis - Global and China Pearl/Effect Pigments Industry Research Conclusions Companies Mentioned - Altana - Aoke - BASF - CQV - Chenguang - Impact Colors - Kelly - Kuncai - Longhua - Merck - Oxen - Rika - Ruicheng - Sudarshan - Sun Chemical - Tiancai - Volor For more information visit http://www.researchandmarkets.com/research/zzsscw/global
MRK: 59.26 (-0.31)
Stock Market News for November 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 9:10AM CST
Bank of Japan’s unanticipated expansion in monetary stimulus helped benchmarks to finish at record highs on Friday
VRX: 128.77 (-3.14), HAL: 53.17 (+0.80), XOM: 96.26 (+1.19), SLB: 96.98 (+0.34), YHOO: 47.93 (+0.47), GS: 191.00 (+1.16), V: 250.09 (+0.56), CMI: 146.64 (+2.52), CHK: 22.76 (unch), MRK: 59.26 (-0.31), EOG: 98.97 (+2.87), ABBV: 62.71 (+0.17), CAT: 100.91 (+1.50), CVX: 118.53 (+1.48), AAPL: 108.70 (-0.16), MA: 85.75 (-0.24)
The Zacks Analyst Blog Highlights: Goldman Sachs Group, Visa, DuPont, Merck and Pfizer
PR Newswire - Mon Nov 03, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Goldman Sachs Group, Inc. (NYSE:GS-Free Report), Visa Inc. (NYSE:V-Free Report), DuPont (NYSE
D-Free Report), Merck & Co. (NYSE:MRK-Free Report) and Pfizer Inc. (NYSE FE-Free Report). V: 250.09 (+0.56), MRK: 59.26 (-0.31)
